The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...
Sanofi (NASDAQ: SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has ...
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...
Investor's Business Daily on MSN
Kymera rockets, pulling Nurix higher. Does it have the next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...
Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...
Canaccord raised the firm’s price target on Regeneron (REGN) to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect ...
Morgan Stanley flagged upside risks if pipeline data impresses, Dupixent intellectual property proves more durable, or Eylea HD adoption accelerates. Downside risks include trial setbacks, competitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback